Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Equity Income (2018 - 2022)

Historic Equity Income for Arcturus Therapeutics Holdings (ARCT) over the last 5 years, with Q2 2022 value amounting to -$131000.0.

  • Arcturus Therapeutics Holdings' Equity Income rose 6006.1% to -$131000.0 in Q2 2022 from the same period last year, while for Dec 2022 it was -$515000.0, marking a year-over-year decrease of 20000.0%. This contributed to the annual value of -$515000.0 for FY2022, which is 20000.0% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Equity Income of -$131000.0 as of Q2 2022, which was up 6006.1% from -$384000.0 recorded in Q1 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Equity Income peaked at $1.2 million during Q1 2021, and registered a low of -$384000.0 during Q1 2022.
  • Moreover, its 5-year median value for Equity Income was -$143000.0 (2021), whereas its average is -$46000.0.
  • Over the last 5 years, Arcturus Therapeutics Holdings' Equity Income had its largest YoY gain of 86564.42% in 2021, and its largest YoY loss of 22800.0% in 2021.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Equity Income stood at -$255000.0 in 2018, then surged by 81.57% to -$47000.0 in 2019, then tumbled by 112.77% to -$100000.0 in 2020, then crashed by 55.0% to -$155000.0 in 2021, then grew by 15.48% to -$131000.0 in 2022.
  • Its Equity Income stands at -$131000.0 for Q2 2022, versus -$384000.0 for Q1 2022 and -$155000.0 for Q4 2021.